News und Analysen
EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Q3 2022 Financial Results and Operational Progress on November 22, 2022
Vistagen Reports Second Quarter Financial Results and Provides Corporate Update
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
EQS-News: Heidelberg Pharma and Partner Magenta to Present Initial Clinical Data on their Antibody Drug Conjugates at the ASH Annual Meeting 2022
Valbiotis lanciert Kapitaleinwerbung von rund 8 Mio. Euro zur Beschleunigung seiner Marketingstrategie
Valbiotis (FR0013254851 – ALVAL, PEA/KMU-berechtigt) (Paris:ALVAL), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und Bekämpfung von
Valbiotis schließt Finanzierungsrunde über 9,7 Millionen Euro erfolgreich ab
Pflichtmitteilung:
Valbiotis (FR0013254851 – ALVAL, qualifiziert für PEA/SME), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und
Valbiotis Successfully Completes a Fundraise of 9.7 Million Euros
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
EQS-News: Burcon Reports Fiscal 2023 Second Quarter Results
Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. further extend their stay of pending litigation to provide additional time for the parties to finalize their litigation settlement
EQS-News: Burcon NutraScience Corp.: Burcon Appoints Specialty Protein Executive Kip Underwood as Chief Executive Officer
EQS-News: Heidelberg Pharma’s Partner Telix Reports Positive Data on the Pivotal ZIRCON Study
Sensorion Announces US FDA Grants Rare Pediatric Disease Designation to OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing
Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil)
Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Vistagen to Present at Stifel 2022 Healthcare Conference
Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety
Pharnext announces that Neovacs has set-up a management trust to manage the Pharnext securities issued and the rights and obligations of Neovacs under the financing agreement signed on September 30th,
Valbiotis präsentiert auf der Jahrestagung der American Association for the Study of Liver Diseases (AASLD) signifikante präklinische Ergebnisse für seinen Wirkstoff TOTUM•448 gegen Fettlebererkrankungen (NAFL und NASH)
Regulatorische Nachrichten:
Valbiotis (FR0013254851 – ALVAL, qualifiziert für PEA/SME), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und
Valbiotis Will Present Significant Preclinical Results for Its Active Substance TOTUM•448 Against Fatty Liver Diseases (NAFL and NASH), at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
Vistagen to Host Concordia Live Webinar on Mental Health with Leaders from McKinsey Health Institute, WEVO, and In KidZ
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. extend their stay of pending litigation to provide additional time for the parties to finalize their settlement
EQS-News: Burcon NutraScience Corp.: Burcon Announces Fiscal 2023 Second Quarter Conference Call to be Held on November 7, 2022
Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission
Sensorion Announces Approval to Initiate amended Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity in France
Regulatory News:
Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Actinogen Medical (AGW): re-initation — Cognitive enhancer targeting key diseases
Vistagen Announces Results of Voting from 2022 Annual Meeting of Stockholders and Partial Adjournment to October 28, 2022
Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression